Procyon Dog Pi/L Data Sheet
Presentation
Procyon Dog Pi/ L is a combination vaccine for injection after reconstitution of the freeze-dried form in the liquid vaccine. It comprises:
One vial of a freeze dried fraction containing live attenuated strains of canine parainfluenza virus (Philips Roxane strain)
One vial of a liquid fraction containing inactivated strains of Leptospira canicola (strain 115) and Leptospiraicterohaemorrhagiae (strain 117), with aluminium hydroxide adjuvant, acting as diluent
Uses
For the active immunisation of dogs from 6 weeks of age:
Immunity has been demonstrated from 3 weeks after the primary vaccination course (serological response only) for parainfluenza and 4 weeks after the primary course Leptospira interrogans serovars canicola and icterohaemorrhagiae.
Duration of immunity is at least 12 months by challenge for parainfluenza and Leptospira interrogans serovarscanicola and icterohaemorrhagiae.
Dosage and administration
Each dose is prepared by reconstituting a vial of freeze dried vaccine with a vial of liquid vaccine. The reconstituted vaccine should be gently shaken and given immediately by subcutaneous or intramuscular injection. Use the vaccine immediately after reconstitution.
Dose - 1ml
Primary vaccination:
Dogs and puppies 6 weeks of age and over:
Administer one dose of Procyon Dog Pi/L with a second dose 3 weeks to 4 weeks later, but not before 10 weeks of age.
Booster vaccination:
A single dose of 1ml is recommended at 12 month intervals.
Parainfluenza, Leptospira canicola and L. ic-terohaemorrhagiae: boost annually
Contra-indications, warning, etc
Contra-indications
Do not use in dogs that have been treated with immuno-suppressive drugs or hyperimmune serum within the last month.
No information is available on the use of the vaccine in pregnant bitches. Do not use in pregnant or lactating bitches. Pregnant bitches should not come into contact with recently vaccinated animals.
Do not mix with any other vaccine/immunological product except diluent supplied with the product.
Warnings
Only healthy dogs should be vaccinated. Vaccination may not be effective in dogs incubating disease at the time of vaccination.
Following primary vaccination, dogs should remain isolated from possible sources of infection for at least 7 days.
Avoid intradermal vaccination.
Occasional hypersensitivity reactions may rarely occur. Appropriate treatment such as adrenaline or antihistamine should be administered without delay.
A mild (<1cm3), transient, local swelling may infrequently be seen at the injection site after the first intramuscular vaccination, which resolves completely without complication within a maximum of 3 weeks. Swelling commonly occurs at the injection site after the first or second subcutaneous vaccination; this swelling was up to 7.7 cm3(4 cm diameter) after the first vaccination and resolved within 2 weeks without complication. In rare cases the swelling may be severe.
In rare cases diarrhoea may be observed and after intramuscular vaccination a single case (1%) of transient (1-2 day) lameness was observed.
No systemic reactions to vaccination were seen in trials following subcutaneous administration.
Following vaccination, CPi may be excreted but will not spread.
In the case of accidental self-injection or ingestion, seek medical advice immediately and show the package insert or label to the physician.
Keep out of reach of children.
For animal treatment only.
Withdrawal period
Not applicable.
Pharmaceutical precautionsStore and transport refrigerated between +2 °C and +8 °C. Protect from light. Do not freeze.
Any unused product or waste material should be disposed of by boiling, incineration or immersion in an appropriate disinfectant in accordance with national requirements.
Legal category
POM-V - To be supplied only on veterinary prescription
Packaging Quantities
Pack size: 25 doses
Each dose is a combination of one vial of freeze dried fraction and one vial of diluent fraction, containing 1ml.
Further information
No information is available on the safety and efficacy from the concurrent use of this vaccine with any other. It is therefore recommended that no other vaccines should be administered within 14 days before or after vaccination.
In any animal population there may be a small number of individuals which fail to respond fully to vaccination. Successful vaccination depends upon correct storage and administration of the vaccine together with the animal’s ability to respond. This can be influenced by factors such as genetic constitution, intercurrent infection, age, nutritional status, concurrent drug therapy and stress.
The presence of maternally derived antibodies (MDA) in young puppies may also interfere with the development of a protective immune response following vaccination. Puppies in which high levels of maternal antibodies are to be expected should be vaccinated at the age of 7 weeks at the earliest.
Intramuscular vaccination gives a slightly higher serological response. If particularly high levels of MDA are suspected or measured then intramuscular vaccination is recommended and/or vaccination should be delayed appropriately.
Marketing authorisation number
Vm 00201/4201
